ReviewJournal of diabetes and metabolic disorders2025
Probiotics and functional foods in metabolic disease: emerging solutions for obesity and diabetes.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The effects of cocoa products in individuals with metabolic syndrome and related diseases: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2026Review
- Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers.Biology · 2026Review
- Functional fermented foods in public health nutrition: key biomolecular mechanisms, gut microbiota interactions, and implications for metabolic disease prevention.Frontiers in nutrition · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global epidemics of obesity and type 2 diabetes (T2D) call for innovative solutions apart from conventional treatments. New research shows that probiotics and functional foods are crucial for controlling metabolic health by reducing inflammation, preserving glucose levels, and adjusting the gut flora. This review investigates the complicated link between gut flora and metabolic illnesses and how functional diets and probiotics help. Furthermore investigated is clinical data supporting their efficacy in controlling diabetes and obesity, therefore stressing both the favourable results and the still existing issues. By addressing the heterogeneity in probiotic strains, personalizing treatments, and considering regulatory issues, this review emphasizes the potential of probiotics and functional foods for preventing and treating metabolic illnesses included in regular medical practice. Increasing evidence points towards specific probiotic strains and functional food ingredients that can mitigate gut dysbiosis, systemically decrease inflammation, and improve metabolic parameters in diabetes and obesity. To maximize therapeutic efficacy and compensate for inter-individual heterogeneity of treatment response, this review examines clinically effective dosing and delivery formats. The article expresses a critical perspective of the issues associated with standardization, safety assessment, and compatibility with traditional treatment protocols. We conclude by outlining the steps taken in order to translate these interventions into public health guidelines and individualized eating regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.